Heisz Leslie Stone - 12 May 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
12 May 2023
Net transactions value
$0
Form type
4
Filing time
15 May 2023, 18:22:26 UTC
Previous filing
04 May 2023
Next filing
10 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Award $0 +2,803 +10% $0.000000 30,283 12 May 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Director Stock Option (Right to Acquire) Award $0 +1,795 $0.000000 1,795 12 May 2023 Common Stock 1,795 $89.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
F2 These options were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.